Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer: KOL Insight

Product Code:
596200416
Publication Date:
July 2015
Format:
PDF, 209 Pages
Price:
€6995

The rapidly evolving non-small cell lung cancer (NSCLC) treatment algorithm is becoming increasingly complex and fragmented. Every advancement brings a new set of questions and concerns. This comprehensive report presents all the facts as they stand today, plus expert insights on the likely state of affairs tomorrow.

Which therapies are most likely to make a significant difference in the NSCLC field? Will we learn to use them to their fullest potential and in the optimal sequence? Can we afford them?

Non-Small Cell Lung Cancer: KOL Insight provides a review of the marketplace and the pipeline with an emphasis on established and emerging treatment pathways. Interviews with 12 KOLs add future-facing perspective to the data. The result is an insider’s guide to the intricacies of a critical and complex market.

Reqeust Sample Pages

Top Benefits

  • Understand how your product is perceived, or is likely to be perceived, by the marketplace
  • Learn about the strengths and weaknesses of your competitors
  • Consider new positioning approaches that will put your product in the most favorable light possible
  • Understand opportunities and threats in the marketplace
  • Gain the insights required to better direct your sales and/or marketing teams toward success

Critical Questions Answered

  • Which new drugs are likely to disrupt or reshape the treatment algorithm for NSCLC?
  • Which clinical trials have the greatest potential to impact the future treatment of NSCLC?
  • How is the use of current targeted and immune therapies evolving, or likely to evolve?
  • What are the experts’ greatest concerns about new and future therapies?
  • How will biomarkers and patient segmentation affect the future of treatment of NSCLC?

Key Areas Covered

  • Currently used, and late-stage pipeline, targeted and immune therapies for NSCLC
  • Summaries and analyses of the most significant, ongoing late-stage clinical trials
  • Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
  • Considerations of treatment cost versus efficacy

Current Treatments Covered

Pipeline Therapies Covered

Immunotherapy

  • Opdivo (nivolumab; Bristol-Myers Squibb)

EGFR mutation-positive NSCLC

  • Tarceva (erlotinib; Astellas/Roche)
  • Iressa (gefitinib; AstraZeneca)
  • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)

ALK-positive NSCLC

  • Zykadia (ceritinib; Novartis)

ALK and EGFR mutation-negative NSCLC

  • Avastin (bevacizumab; Roche)
  • Vargatef (nintedanib; Boehringer Ingelheim)
  • Cyramza (ramucirumab; Eli Lilly)

Immunotherapy

  • Keytruda (pembrolizumab; Merck & Co.)
  • Atezolizumab (MPDL3280A; Roche)
  • Durvalumab (MEDI4736; AstraZeneca)
  • Yervoy (ipilimumab; BMS)

EGFR mutation-positive NSCLC

  • Mereletinib (AZD9291; AstraZeneca)
  • Rociletinib (CO-1686; Celgene/Clovis Oncology)
  • Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
  • Patritumab (AMG 888; Amgen/Daiichi Sankyo)

ALK-positive NSCLC

  • Alectinib (RO5424802/CH5424802; Roche)

ALK and EGFR mutation-negative NSCLC

  • Selumetinib (AZD6244; Array/AstraZeneca)
  • Veliparib (ABT-888; AbbVie)
  • Gemzar (necitumumab; Eli Lilly)
  • Bavituximab (Peregrine)
  • Abemaciclib (LY2835219; Eli Lilly)
  • Ganetespib (STA-9090; Synta)

 

Key Opinion Leaders

KOLs from North America:

  • Paul Bunn, Distinguished Professor, Division of Medical Oncology, University of Colorado Edward Garon, Associate Professor, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Giuseppe Giaccone, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, Washington, DC
  • Leora Horn, Assistant Professor of Medicine (Haematology/Oncology) and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Tennessee
  • Joan Shiller, Deputy Director of the Simmons Comprehensive Cancer Center and Division Director of Hematology/Oncology, University of Texas-Southwestern Medical Center, Texas
  • Mark Socinski, Professor of Medicine and Thoracic Surgery, University of Pittsburgh School of Medicine, Pennsylvania

KOLs from Europe:

  • Ahmed Awada, Professor and Head of the Medical Oncology Clinic, Jules Bordet Institute, Brussels & Free Universities, Brussels, Belgium
  • Federico Cappuzzo, Professor and Director of Medical Oncology, Ospedale Civile di Livorno, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
  • Solange Peters, Head of Thoracic Malignancies Program, Department of Oncology, University of Lausanne, Switzerland
  • David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, France
  • Nick Thatcher, previously held the post of Professor of Medical Oncology at the Christie Hospital NHS Trust in Manchester, England
  • Anonymous KOL, Germany

Reqeust Sample Pages

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Regular updates to cover significant market events such as new product approvals or pivotal research results will be covered with primary market research with preeminent KOLs
  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, July 2015
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
therapy-trends-150.jpgTherapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

 




customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved